Coronavirus bootcamp? New serological test conducted with the IDF

Written on | ,

The new test in the Israel Defense Forces aims to detect antibodies and immune response to coronavirus

Tel Aviv University researchers have developed a new test to add to the current diagnostic arsenal used to detect coronavirus infection. The test is serological — based on blood samples — and measures the presence of antibodies against the virus.

It can be used to assess the full extent of the spread of the virus in the general population. A TAU team led by Prof. Motti Gerlic and Prof. Ariel Munitz, both of TAU’s Sackler Faculty of Medicine, together with researchers at the Israel Medical Corps will use this novel assay to conduct the first widespread test of Israel Defense Forces soldiers for development of antibodies to the coronavirus.

A military rescue

The tests are being carried out in collaboration with the Israel Medical Corps to minimize outbreaks across units, maintain full operational capability and prepare for future epidemics.

The novel electrochemiluminescence-based serological test, developed in collaboration with Biological Industries, Israel, is capable of detecting the full range of antibodies which are produced by the immune system, namely IgM, IgG and IgA. The new test is accurate, reliable and quick (it only takes an hour) and is currently being evaluated by the US Food and Drug Administration (FDA) for use in the U.S.

A faster, more accurate test

“Until now, the common method of detection, through nasal swabs, was based on quantitative PCR analysis, which amplifies viral genes,” explains Prof. Gerlic. “While this method is excellent in initial phases of viral spread, it has major drawbacks: decreased accuracy, as swabs are taken five days after the emergence of symptoms; expensive; and it does not convey any data about the level of immunity of an individual.”

The new test will allow researchers to monitor and analyze the immunological response of both COVID-19 patients and healthy asymptomatic individuals to answer the question: How much of the public has been exposed to the virus? While tools exist for the diagnosis of infected individuals, the host response to the virus remains unclear – specifically, the association between the emergence of different antibodies and disease severity.

The test will provide an overview of various trends in the general population and in the IDF, in particular, as it identifies antibodies weeks after exposure to the virus and the development of any symptoms. The new serological test will afford the IDF an indication as to which soldiers (symptomatic and asymptomatic) were exposed to the disease, and which potentially developed resistance to the virus, while identifying those soldiers who have not yet been infected and may be at risk.

Quality and quantity

“A fear of contagion in the IDF could impair the operational capability of certain units,” concludes Prof. Munitz. “The tests we carried out will allow the army to identify those soldiers who have developed antibodies and possibly even viral resistance and who can continue their duties without risk of infection and spread of the disease. As we expand the testing and our database, the IDF will be able to increase its operations while balancing its concern for soldiers’ health.”

Lt. Col. Dr. Ariel Furer of the Israel Medical Corps: “This study allows us to evaluate a significant tool in the fight against the corona epidemic. The antibody tests used in this study may shed light on the extent of IDF morbidity as a result of the virus and will help prepare the IDF and the Medical Corps for another epidemic. Collaborations with researchers at the forefront of the fight against corona position the Medical Corps as a leading health organization, allowing it to test the use of the most advanced means available to safeguard soldiers’ welfare and health. As a result of this study, we will be able to assess the possibility of incorporating such tests into routine checks in the fight against corona.” 

Related posts

COVID-19 Immunity Varies Among Genders and Age Groups

July 26, 2021

New study found differences between women and men in the level of COVID-19 antibodies

July 15, 2021

How Will We Brave the Post-COVID Era?

May 31, 2021

British Variant 45% More Contagious than Original Virus

April 28, 2021

COVID-19 Vaccinations at TAU

March 24, 2021

Covid-19 Vaccination of Nursing Mothers May Protect Babies

March 24, 2021

Academic First Responders

January 14, 2021

TAU Study Proves that Light Can Kill Coronavirus

December 14, 2020

COVID-19 Takes TAU’s Legal Clinics into High Gear

December 7, 2020

Parents show love less during COVID-19: TAU Study

December 2, 2020

Study: Women Suffer More from COVID-related Orofacial Pain

November 12, 2020

Global First: Center for Combating Pandemics

October 22, 2020

TAU Researchers Discover Antibody Combo that Fights COVID-19

October 12, 2020

Immunity Memory Cells Stay Stable Over Time After Recovery From COVID-19

October 12, 2020

TAU Joint Study: COVID-19 Deaths Dive on Weekends

September 10, 2020

TAU Wins 3M Grant to Accelerate COVID-19 Vaccine Development

September 9, 2020

TAU Inaugurates Shmunis School of Biomedicine and Cancer Research

September 8, 2020

New school for Biomedicine and Cancer Research at Tel Aviv University

August 13, 2020

TAU Researcher Invents Environmentally-Friendly Sanitizer

August 11, 2020

TAU Researcher Fights Epidemics Both Viral and Virtual

July 23, 2020

Tel Aviv University presents an analysis of the reaction of human antibodies to the coronavirus

July 5, 2020

New TAU study tracks coronavirus spread patterns in Israel

May 21, 2020

TAU partners with pharma company to develop COVID-19 vaccine

May 13, 2020

What about the environment?

May 11, 2020

A world first: TAU to establish multidisciplinary Epidemic Research Center

May 11, 2020

Tel Aviv University joins national Coronavirus testing system

May 7, 2020

TAU lab identifies effective antibodies from recovered Coronavirus patients

May 7, 2020

TAU Student, COVID-19 Sprint Invent Disposable Ventilators to Help Treat Coronavirus Patients

April 28, 2020

TAU to partner with InnoCan Pharma on revolutionary COVID-19 treatment

April 21, 2020

TAU Scientist Awarded U.S. Patent for Novel Coronavirus Vaccine Design

April 19, 2020

Donated Equipment Aids in Urgent Coronavirus Research

April 6, 2020

Tel Aviv University Sets Up Emergency Lab to Expand COVID-19 Testing

April 5, 2020

Students Volunteer to Increase and Improve Coronavirus Testing Across Israel

March 22, 2020

What’s more important? Privacy vs. public health

March 17, 2020

Pursuing the Unknown

Copyright ©  Tel Aviv University Trust. All rights reserved.
Registered charity number 314179.